Why is there discussion on this? Didn't this earlier research prove the benefit of immediate statin therapy? Or do you INCOMPETENTLY NOT KNOW ABOUT IT?
Association Between Acute Statin Therapy, Survival, and Improved Functional Outcome After Ischemic Stroke: The North Dublin Population Stroke Study March 2011
Or don't you have a functioning stroke doctor who incompetently missed this research from 2011?
1. Statins.
tested in rats from 2003
http://Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke
Simvastatin Attenuates Stroke-induced Splenic Atrophy and Lung Susceptibility to Spontaneous Bacterial Infection in Mice
Or,
Simvastatin attenuates axonal injury after experimental traumatic brain injury and promotes neurite outgrowth of primary cortical neurons
October 2012
tested in humans, March 2011
http://www.medwirenews.com/39/91658/Stroke/Acute_statin_therapy_improves_survival_after_ischemic_stroke.html
And now lost even to the Wayback Machine
So, I think this below is the actual research.
Association Between Acute Statin Therapy, Survival, and Improved Functional Outcome After Ischemic Stroke April 2011
The latest here:
Low-dose statins combined with repetitive transcranial magnetic stimulation reduce post-stroke depression
Chaohua Cui
Chuhua Cai2†
Tonghua Long- 1Life Science and Clinical Medicine Research Center, Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, Guangxi, China
- 2Drug Clinical Trial Management Office, The Second Affiliated Hospital Of Guangxi University of Science and Technology, Liuzhou, Guangxi, China
Background: The effectiveness of statins in preventing post-stroke depression (PSD) remains controversial. Lower testosterone levels caused by statins could potentially increase the risk of PSD. Low-dose statins could offer better benefits due to their lesser impact on testosterone levels. Repetitive transcranial magnetic stimulation (rTMS) has been shown to reduce PSD in the acute stage. The combination of low-dose statins and rTMS may provide a promising therapeutic option for patients with PSD.
Methods: Data were collected from ischemic stroke patients. Unsupervised machine learning methods were employed to explore the risk factor of PSD. Our prospective cohort study collected data from ischemic stroke patients over 3 years. The patients’ conditions determined the prescription of statins. The outcomes measured included the incidence of PSD, favorable functional outcome (FFO) at 6- and 12-months post-onset.
Results: A total of 545 patients were included in the study. The mean age was 60.99 ± 12.768 years, and 31.9% of the participants were female. The combination of low-dose statins and rTMS subgroup had the lowest incidence of PSD at both 6 and 12 months (p < 0.001). In multivariable logistic regression, the combination of low-dose statins and rTMS was inversely related to PSD at 6 months (OR = 0.370, p = 0.003) and 12 months (OR = 0.386, p = 0.004).
Conclusion: The combination of statins and the rTMS group related the lower incidence of PSD in stroke patients. Combining low-dose statins and rTMS could reduce PSD and further improve the prognosis of ischemic stroke patients.
Introduction
Post-stroke depression (PSD) is a common complication among ischemic stroke patients. These patients have worse functional outcomes and higher mortality rates than those without PSD (1). Antidepressants are the primary treatment for PSD patients. However, longer treatment cycles and more side effects affect the compliance of PSD patients (2). Additionally, an increasing number of PSD patients develop tolerance to antidepressants (2). These PSD patients require a safer and simpler treatment.
Statins could affect the incidence of PSD of stroke patients (3–6). Different studies have reached distinct conclusions about the effect. One Asian study suggests that statins increase the incidence rate of PSD (4). Other studies have shown the opposite result, indicating that statins decrease the incidence rate of PSD (5, 6). The various effects of statins and different types of studies could partly explain these contradictory conclusions (7). Several studies have demonstrated that reduced testosterone levels may elevate the risk of PSD (8, 9). Therefore, low-dose statins may offer greater benefits to PSD patients, as they exert a less pronounced effect on testosterone levels (8, 9).
Statins may have varying effects on PSD depending on the stage of stroke. The use of statins before a stroke may reduce the risk of PSD, whereas post-stroke use could potentially increase it (10, 11). Thus, identifying an effective treatment strategy for patients in the acute phase of stroke with PSD is essential. Our analysis of a retrospective cohort, utilizing unsupervised machine learning methods, revealed that stroke patients receiving statins during the acute phase in conjunction with rTMS exhibited a lower incidence of PSD. Several studies have indicated that high-frequency rTMS is an effective treatment for PSD, particularly for patients in the acute phase of stroke (12–14). rTMS may counteract the adverse effects of statins in acute PSD patients, while statins could provide longer-term benefits for those in the chronic phase of PSD. Consequently, combining statins with rTMS may provide a comprehensive solution to these challenges.
This study aims to explore whether the combination of statins and rTMS can decrease PSD in ischemic stroke patients. Additionally, we aim to analyze further whether the combination of low-dose statins and rTMS better affects PSD patients.
Methods
Cohort 1: retrospective explored cohort
Patients
The study cohort was a retrospective observational cohort. The cohort comprised consecutive patients with ischemic stroke. Patients were recruited from the Neurology and Rehabilitation Departments of the Affiliated Hospital of Youjiang Medical University for Nationalities between January 1, 2018, and May 30, 2019.
The inclusion criteria included ischemic stroke patients aged 18 years or older who had undergone head CT or MRI examinations, met the WHO ischemic stroke diagnostic criteria and received conventional medicine and rehabilitation therapy post-admission. The exclusion criteria were as follows: (1) patients with a recent history of depression before onset; (2) patients unable to be evaluated for depression due to aphasia, disturbance of consciousness, cognitive disorder, or other conditions; (3) patients who taken other lipid-lowering drugs such as fenofibrate; (4) patients with intracerebral hemorrhage, subarachnoid hemorrhage, or severe systemic disease; (5) Patients who are intolerant to statins or rTMS treatment; (6) patients who withdrew from the study or could not provide outcome events.
Data collected
Baseline patient data were collected from electronic medical records, including demographic information, vital signs, and laboratory data. The data collected at admission included age, gender, heart rate, and blood pressure. Critical laboratory data collected at admission included PLT (platelet), INR (international normalized ratio), ALT (alanine aminotransferase), AST (aspartate aminotransferase), CRP (C-reactive protein), among others. Blood lipid levels, including TC (total cholesterol), TG (triglycerides), HDL-C (high-density lipoprotein cholesterol), and LDL-C (low-density lipoprotein cholesterol), were recorded at admission and discharge. Comorbidities, such as renal insufficiency, epilepsy, and pneumonia, were also documented. Medical histories and medication profiles were obtained using structured questionnaires completed by patients or their relatives. Two experienced neurologists, blinded to the patient’s conditions and outcomes, collected and evaluated these data.
Post-stroke depression
The diagnosis of post-stroke depression (PSD) was identified using ICD-9-CM codes 296.2, 296.3, 300.4, or 311. The Mini International Neuropsychiatric Interview (MINI) (6–8), a structured diagnostic psychiatric interview based on the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV), was also used. According to these criteria, patients were diagnosed with major depression if they presented one core symptom and at least four additional depressive symptoms. Alternatively, patients were diagnosed with minor depression if they exhibited at least one core symptom and between two and four additional symptoms. PSD was defined as encompassing both major and minor depressive disorders.
Classify data by unsupervised machine learning
We utilized Python 3.8 for our analysis. For cluster analysis, we first standardized all data using the StandardScaler module from the sklearn library, and then classified data using Hierarchical Clustering methods (AgglomerativeClustering module, sklearn library). The heatmap illustrated the distinct characteristics among the classified patient groups. We compared outcome events across the different identified groups. Grouping can yield clinical significance by clarifying differences in PSD among patient groups. Subsequently, we applied chi-square tests and t-tests to further analyze the factors within the selected groups. Significant differences were found in statin use and rTMS across the Hierarchical Clustering groups. We subsequently validated the impact of statin use and rTMS on the incidence of PSD.
Cohort 2: prospective validated cohort
Study subjects
This study was a prospective cohort study. Ischemic stroke patients were recruited from the neurology and rehabilitation departments of affiliated hospitals of Youjiang Medical University for Nationalities. Patients were enrolled from January 2020 to December 2022 and followed up until December 2023.
Patients who took statins after admission were assigned to the statin group and the remaining patients were assigned to the control group. The study included only patients who did not take statins before admission. Patients were prescribed statins and specific types based on the guidelines for the management of stroke (15).
The inclusion criteria and exclusion criteria were similar as cohort 1.
Baseline data
Baseline patient data were similar as cohort 1.
We evaluated patients’ NIHSS (National Institutes of Health Stroke Scale) scores and mRS (Modified Rankin Scale) scores at admission. Two experienced neurologists, blinded to patients’ conditions and outcomes, collected and evaluated these clinical scale scores.
Statin use
We collected data on patients’ statin use during hospitalization and follow-up. Low-dose and medium-high-dose statins were defined according to the ACC/AHA guidelines on statin intensity (16). The types of statins used in our cohort included atorvastatin, rosuvastatin, simvastatin, and others. Statins were classified into lipophilic (atorvastatin, simvastatin, pitavastatin, lovastatin) and hydrophilic (rosuvastatin) categories. For patients whose statin type or dosage was adjusted during their course of treatment due to changes in their condition, we typically record the statin type or dosage used at the first administration during hospitalization. If the duration of statin use after the change in type or dosage exceeds 70% of the total usage time, the changed type or dosage will be recorded. Lower statin compliance was defined as using statins continuously for less than 40% of the follow-up period. The cohort did not include patients with lower statin compliance. When patients experience significant side effects from statin use and need to discontinue the medication, they are withdrawn from the cohort.
rTMS
Multiple rTMS protocols have been proposed for treating post-stroke depression; this study adopted the treatment approaches from several well-powered studies with robust conclusions (12–14). All patients underwent rTMS therapy for 4 weeks, with five sessions per week, totaling 20 sessions. rTMS was administered to the left dorsolateral prefrontal cortex (DLPFC) at 10 Hz, with magnetic stimulation strength set at 80–100% of the motor threshold level. Each daily treatment included 20 sequences (20 min), each consisting of 4 s of continuous stimulation followed by a 56-s interval (12–14). When patients experience intolerable side effects from transcranial magnetic stimulation therapy or are deemed unsuitable for further treatment by a physician, they will be withdrawn from the cohort.
Outcome events
The primary outcome was the incidence rate of PSD at 6- and 12-months post-onset. The secondary outcomes included favorable functional outcomes (FFO) at 6- and 12-months post-onset. A favorable functional outcome was a modified Rankin Scale (mRS) score of less than 3. Outcome events were collected post-discharge through face-to-face interviews.
Statistical analysis
Statistical analyses were conducted using SPSS 23.0 for Windows. The threshold for statistical significance was set at p < 0.05.
Baseline character
Continuous variables (e.g., blood pressure, laboratory measures) normally distributed between two groups were analyzed using a t-test and expressed as mean ± standard deviation (SD). Continuous variables (e.g., NIHSS) that were abnormally distributed between two groups were analyzed using the Mann–Whitney U test and expressed as the median and interquartile range (IQR). Categorical variables (e.g., gender, history of disease) and ordinal variables (e.g., mRS) were analyzed using the chi-square test and expressed as numbers and percentages.
Outcome variables
A chi-square test was employed to compare the incidence rates of PSD, optimism, and FFO between the two groups. Additionally, we compared the incidence of post-stroke depression across various subgroups. These subgroups were categorized by different doses, type of statins and whether patients underwent repetitive transcranial magnetic stimulation treatment.
We employed multivariate logistic regression analysis to control for confounding factors. In cases where the extreme data exhibited significant imbalance, subgroup analysis and propensity score matching were considered for data processing. However, since the validation cohort did not show a notable imbalance in extreme risk factors, only multivariate logistic regression was used for data analysis.
Logistic regression was used to analyze the relationship between the combination of low-dose statins and rTMS, or other risk factors, and the incidence rate of PSD at different time points. Eligible factors for multivariable regression were screened as follows: (1) a p-value of less than 0.05 in univariable logistic regression; (2) factors selected using LASSO regression; (3) factors meeting criteria (1) and (2). The eligible data were then analyzed using multivariable logistic regression. Odds ratios (ORs), 95% confidence intervals (CIs), and p-values were calculated using logistic regression.
Results
Cohort 1
The exploratory cohort included 117 patients. Thirty-two were female (27.4%), and the mean age was 63.15 ± 11.002 years.
The heatmap suggested that two groups (HCgroup1 and HCgroup2) were optimal for hierarchical clustering methods (Figure 1). The heatmap also indicated significant distinctions between statins and rTMS (Figure 1). Comparing the incidence of PSD between the two groups, HCgroup1 (3.4%) had a significantly lower rate of PSD (p < 0.001) than HCgroup2 (17.7%).
No comments:
Post a Comment